Navigation Links
Renowned Chinese Herbal Medicine Development Specialist Joins China Health Resources
Date:2/13/2008

SUINING, China, Feb. 13 /Xinhua-PRNewswire/ -- China Health Resources Co., Ltd. (CHRI; OTC Bulletin Board: CHRI) announced that Jia Minru, famous professor of the Chinese Medicine University and authoritative Chinese physician, joined CHRI recently to be responsible for deep development, high-tech development and systematic research of deep processed products of Chuan DAR GAP.

The joining of Jia Minru will certainly strengthen the research and development force of CHRI. With the technological advantage of CHRI, Jia will take part in realizing the commercial development with more advanced technology and more commercial value for Suining Chuan DAR and its processed products.

Jia has more than 40 years of research experience in medicine and herb resource development. He was the Advisor of the Chinese Medicine Academy, the Dean of Chinese Medicine University, the deputy dean of Chinese Medicine Association, Director of Chinese Medicine and Herb Committee, and a Member of Sichuan New Medicine Assessment Center.

About the Company

China Health Resources Co., Ltd. (CHRI) was incorporated on April 24, 2001. It is one of China's leading industrialized agricultural corporations. CHRI focuses on the production and further processing of Dahurian Angelica Root (DAR), a herb that is widely used in China, and considered to be an important ingredient in Chinese traditional medicine. CHRI's business plan includes distributing DAR and its processed products to exploit a large market in the areas of treatment of pain, swelling and pustule. Good Agricultural Practice (GAP) is a national compulsory criterion for food and drug industries. The goal of GAP is to help agricultural product companies deal with the usual micro-organism harm so as to enhance safety of agricultural products. CHRI has accomplished GAP certification of Chuan DAR, making DAR products and related production technology of the Company part of the industry criteria.

Statements r
'/>"/>

SOURCE China Health Resources Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Cleveland Clinic Recruits World Renowned Heart Rhythm Specialist to Direct Electrophysiology
2. Childrens Hospital Boston Mourns the Death of Dr. Judah Folkman, World Renowned Researcher and Founder of the Field of Angiogenesis
3. HealthONE(R) Appoints Nationally Renowned Pediatric Cardiologist & Childhood Obesity Expert as First Chief Medical Officer for the Rocky Mountain Hospital for Children(SM)
4. BREATHE Lung Cancer Conference, Nov. 30, Attracts World Renowned Physicians and Speakers
5. World-Renowned Therapist Joins The Center for Children and Families In Its Work With the Nations Poorest Families
6. Thailand: Partners Open Free AIDS Treatment Clinic in Renowned AIDS Temple in Lop Buri
7. China Pharma Holdings, Inc. Receives Chinese SFDA Approval for Generic Bumetanide Injection
8. Linkwell Chairman & CEO Addresses the Association of Chinese Nosocomial Infections Professional Committee
9. What are the essential characteristics of serum PG in Chinese?
10. Rh-Apo2L Named as One of Chinas High-Tech Transforming Products by Chinese Government
11. All-State Properties, L.P. Announces Termination of Reverse Merger With Chinese Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2008)...esults of a 10-year study published in the August ...found that magnesium sulfate administered to women...he risk of cerebral palsy by 50 percent. The Benef...) trial was conducted in 18 centers in the U.S., i...renatal intervention ever found to reduce the inst...
(Date:8/29/2008)... http://www.aronowitzmd.com [Los An...espected experience in plastic surgery procedures ...consideration may be necessary for these patients,...e an established specialty of procedures for after...es, CA (PRWEB) August 29, 2008 -- Bariatric surger...
(Date:8/28/2008)...ues increase 138% versus Q2 2007 - Nine new Cen...RNewswire-FirstCall/ - CRH Medical Corporation,(CR... three and six months,ended June 30, 2008 (all fig...ths ended June 30, 2008 increased 138% to $1,653,8...7. Revenue for the six months ended June,30, 2008 ...
(Date:8/28/2008)...ion will be based in the Northeast region with mor...xt year, HARRISBURG, Pa., Aug. 28 /PRNewswire-USN...ity has hired a Patient Safety Liaison for the,Nor...eport to the,Pennsylvania Patient Safety Reporting...ylvania citizens., "Last year in focus groups wit...
Breaking Medicine News(10 mins):Health News:National study shows magensium sulfate reduces risk of cerebral palsy in premature births 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3
...has been little research about the physical activi...ts are exercising and what // they are doing could...ograms for asthma patients. Doctors from the Cente...nducted a study to look at the physical activity l...
...suffering from back pain, pelvic pressure, frequen...could be to blame. Fibroids are non-cancerous // g...rom very small to the size of a cantaloupe or larg...ne fibroid embolization -- a treatment that’s beco...
...tis is a common health problem worldwide. Both ost...ain and stiffness in patients.There is no cure for...maged cartilage. // A new study could help lead do...t of arthritis. The research pinpoints the molecul...
...study finds angioplasty should be the treatment of...pital they initially go to doesn’t offer angioplas...nother facility for treatment. Research has shown ...hey are treated with angioplasty to open up the cl...
Other Medicine News:
(Date:8/27/2008)...tients in the VELCADE, melphalan and prednisone ar... well as a 30 percent complete response -, CAMBRI...e Takeda,Oncology Company today announced the publ...d, Phase III VISTA(1) trial in this week,s edition...ts showed a significant survival,benefit and a 30 ...
(Date:8/27/2008)...First Phase 3 data, from BLISS-52 trial, expected ...LISS-76, expected by fall 2009 -, ROCKVILLE, Md.,...iences, Inc. (Nasdaq: HGSI ) today announced it h...S-76, the second of two pivotal Phase 3,randomized... patients with,active systemic lupus erythematosus...
(Date:8/26/2008)...IANAPOLIS, Aug. 26 /- Semafore Pharma...national Congress on Targeted Therapies,in Cancer ...ovel,multi-targeted kinase inhibitors that demonst...l studies., A novel and proprietary molecular sca...ing allowing for the design of pan-PI3 kinase inhi...
(Date:8/26/2008)...LO PARK, Calif., Aug. 26 /-... the positive one-year follow-up data,from the CUS...e of the,peer-reviewed journal, EuroIntervention. ...tella, M.D., of University Medical Center Utrecht,...II Investigators from 13 clinical,sites across Eur...
Breaking Medicine Technology:New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 2New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 4New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 5New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 6Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 4Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 5Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 6Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 2Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 2XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 4Blood pressure drug telmisartan shows powerful activity against stroke 1570 1Blood pressure drug telmisartan shows powerful activity against stroke 1570 2Blood pressure drug telmisartan shows powerful activity against stroke 1570 3Ireland Cancer Center researchers advance stem cell gene therapy 1565 1Ireland Cancer Center researchers advance stem cell gene therapy 1565 2Ireland Cancer Center researchers advance stem cell gene therapy 1565 3Wind power explored off Californias coast 1563 1Wind power explored off Californias coast 1563 2Wind power explored off Californias coast 1563 3Wind power explored off Californias coast 1563 4Ceregene Presents Long term Follow up From Phase 1 Trial of CERE 120 in Parkinsons Disease 1050 1Ceregene Presents Long term Follow up From Phase 1 Trial of CERE 120 in Parkinsons Disease 1050 2Ceregene Presents Long term Follow up From Phase 1 Trial of CERE 120 in Parkinsons Disease 1050 3Ceregene Presents Long term Follow up From Phase 1 Trial of CERE 120 in Parkinsons Disease 1050 4
A full, rounded look that adds greater dimension to the breast. Moderate base, with a higher profile than our Style 1600 implant.
The Advanta™ PTFE facial implant is an expanded porous polytetrafluoroethylene,material that is intended for augmentation or repair of the soft tissues of the facial,area. This product is avail
Chin Implants are used for cosmetic augmentation, repairing trauma related injuries and genetic deficiencies. They are inserted through an incision in the mouth below the incisor teeth or through an
The IEC CL40 and FL40 Centrifuge Series from Thermo Electron combines power, safety and versatility to increase your productivity in the lab. Available with a broad array of rotors and accessories fo
Medicine Products: